ELIQUIS .5 mg/1 (Apixaban TABLET, FOR SUSPENSION) .5 mg/1

ELIQUIS .5 mg/1 is an oral medication used to reduce the risk of blood clots. This tablet, for suspension, is formulated for convenient administration and is available in a 28-packet carton. Learn more about its uses and effects.

Strength

.5 mg/1

Pack Size

28 PACKET in 1 CARTON (0003-1028-28) / 1 TABLET, FOR SUSPENSION in 1 PACKET

Manufacturer / TM Owner

E.R. Squibb & Sons, L.L.C.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

ELIQUIS .5 mg/1 is commonly used to prevent blood clots in individuals at risk. It is often prescribed for conditions where clotting could lead to serious health issues. People often ask, 'What is ELIQUIS used for?' and the answer typically involves its role in managing clotting risks.

Side Effects

ELIQUIS .5 mg/1 works by inhibiting certain clotting factors in the blood. Common effects may include reduced clotting activity, which can help manage conditions related to excessive clotting. Always consult a healthcare provider for personalized information.

Precautions & Warnings

Handling ELIQUIS .5 mg/1 requires careful attention to dosage and administration. It is important to follow the prescribed guidelines to avoid potential complications. Store the medication as directed and keep it out of reach of children.

Avoid Interactions

ELIQUIS .5 mg/1 may interact with other medications, including blood thinners and certain pain relievers. It is advisable to discuss all current medications with a healthcare provider to avoid potential interactions. Alcohol consumption should also be moderated.

Frequently Asked Questions

ELIQUIS is used to reduce the risk of blood clots in individuals who are at risk of developing them.

ELIQUIS is typically taken orally, either as a tablet or in suspension form, as directed by a healthcare provider.

Common effects of ELIQUIS may include reduced clotting activity, which can help manage conditions related to excessive clotting.

Yes, it is important to follow the prescribed dosage and administration guidelines to avoid potential complications.

Yes, ELIQUIS may interact with other medications, including blood thinners and certain pain relievers.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.